diagnost tool
bull thesi intact upsid sight
posit analyst day pt
posit analyst day pictur largest remain
pure-play human point-of-car diagnost compani remain close
acquisit aler make desir takeout candid roch
biomerieux lot fun lot good
fortun swung way short amount time compani energ
success execut better almost anyon could expect
expect continu reiter buy rais estim pt
share use multipl adj ep
initi revenue guid prior
think huge flu bridg delta street
upper limit qdel guid impli rev may come
prior assum flu rev affirm
view flu begin expect segment rev
flu vs prior cardiac vs
prior vs prior expect
molecular rev guid gm
ebitda margin opex line think
revenu target initi revenue target doubl
year compound-annual-growth-rate big number given street look
target rev organ
 expect legaci growth driven sofia
molecular includ savanna confid larger global footprint enabl
bolt assay content expect growth flu growth
alr cardiac assay view target appear achiev within
framework prior alr deal pre-savanna launch
lt margin target initi lt target gm ebitda
pro-forma baselin respect think ebitda target could
achiev within year gm target could take year hit
sofia sofia outstand new instrument gain solid uptak
market expect ib sofia end target lt
de-lever show strong disciplin balanc sheet expect
pay debt leverag ratio hover end
respect recal paid debt post sale
leaseback run leverag time acquisit
/- savanna tam big time push savanna target
hospit clinic much smaller instrument time-to-result
min multiplex target
expect launch eu late us
/- alr synergi intact might take bit longer expect cost
synergi in-lin run-rat end
think end run-rat end mostli
semant time bottom line like realiz full
time manufactur yield driven advanc robot oper
price close busi april
diversifi lead manufactur rapid flu
strep pregnanc test physician offic
hospit expand pipelin new test
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
bull thesi intact upsid sight
posit analyst day
reiter buy rate pt
posit analyst day net net believ big pictur
squar intact largest remain pure-play human point-of-car
diagnost compani remain close acquisit aler make
desir takeout candid roch
biomerieux view lot fun lot good fortun
swung way short amount time compani energ success
execut better almost anyon could expect
expect continu reiter buy rais estim pt
use multipl adj ep
initi revenue guid prior
think big bridg delta street upper
limit qdel guid impli rev may come
prior assum flu rev affirm
view flu begin expect segment rev
flu vs prior cardiac vs
prior vs prior also
expect molecular rev guid gm
ebitda margin opex line
think
revenu target initi revenu target
doubl year compound-annual-growth-rate big number given street
look target revenue
growth organ expect achiev
legaci organ growth driven sofia molecular includ savanna
confid larger global footprint enabl bolt assay content
expect growth flu growth alr cardiac assay
view target appear readili achiev within framework
prior alr deal pre-savanna launch
lt margin target initi lt margin target gm ebitda
trend pro-forma baselin respect think
ebitda target could achiev within year gm target could take
year hit
 savanna got makeov much smaller instrument
multiplex target time-to-result min
min believ bullish chanc compet
cepheid genexpert platform howev genexpert massiv instal base
deep molecular assay menu think easi compet
said believ qdel low cost good valu proposit
panel larger cepheid offer today like well receiv
market hospit segment recal nasdaq buy
also recent launch respiratori viru panel newer panther system
certainli meaning battleground savanna realli take hold
market view expect launch savanna eu late
us initi mini-panel std respiratori
vagin pharyng hiv viral load hsv/vzv/syphili lt mrsa diff gi
panel gb hcv tb transplant sepsi bsi indic target
buy unchang target price april
diagnost tool
sweet spot panel size certainli well biofir genmark
target
 alr asset synergi expect cost synergi in-lin
run-rat end think end
run-rat end mostli semant time bottom
line like realiz full time manufactur yield driven
advanc robot oper
announc ngi nex-gen immunoassay upgrad sofia
seek deliv assay stronger accuraci sens/spec
ga would requir cultur back-up reduc time
confirmatori result day minut
sofia expect ib end reiter view instal
adeno pink eye sofia legionella strep pneumo eu lt sofia enhanc
assay rvp flu rsv hmpv sofia vitamin fingerstick whole
blood us strep
de-lever indic expect pay debt leverag
ratio hover end respect recal
paid debt post sale leaseback run
leverag time acquisit
market share gain flu indic increas number flu account
y/i full year grew number flu account
y/i think number even higher post result
given ship flu product competitor could
model chang made fair number adjust model
rev rais revenue estim
prior street prior analyst day expect
street hover ahead earn call rais
revenu estim prior part
function slightli higher revenu molecular cardiac assay
ep rais adj ep
rais adj ep consensu estim
think street adj ep could high
expect manag need ramp spend get savanna
market unit state higher clinic trial cost etc
molecular rev rais molecular assay rev
rev believ segment may
prove conserv given strong uptak solana
rev rais prior mainli due
higher outlook flu rais prior
gross margin rais gm
respect recal guid
ebitda margin rais ebitda margin
maintain ebitda margin yet initi
estim believ trend mid time
alr cardiac assay made small chang rev
manag look establish base cardiac
buy unchang target price april
diagnost tool
revenu year said also indic cardiac
segment could gener revenu prove
true calcul segment could high year
lack visibl inflect rais rev
match manag comment track
though nudg estim back half conservat
buy unchang target price april
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price april
diagnost tool
buy unchang target price april
diagnost tool
buy unchang target price april
diagnost tool
